Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Accumulated Expenses (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Accumulated Expenses for 4 consecutive years, with $162112.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 79.58% to $162112.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162112.0 through Dec 2025, down 79.58% year-over-year, with the annual reading at $3.0 million for FY2025, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2025 was $162112.0 at Neuphoria Therapeutics, down from $497667.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $3.0 million in Q2 2025, with the low at $162112.0 in Q4 2025.
  • Average Accumulated Expenses over 4 years is $967358.4, with a median of $837230.3 recorded in 2022.
  • The sharpest move saw Accumulated Expenses rose 9.14% in 2023, then plummeted 79.58% in 2025.
  • Over 4 years, Accumulated Expenses stood at $880579.5 in 2022, then grew by 9.14% to $961060.9 in 2023, then fell by 17.4% to $793881.0 in 2024, then tumbled by 79.58% to $162112.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $162112.0, $497667.0, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.